HCPCS Level II code A9552 identifies a diagnostic dose of fluorodeoxyglucose F-18 (FDG), billed per study dose up to 45 millicuries, used primarily for positron emission tomography (PET) imaging. This code is important nationally because FDG PET is a widely used molecular imaging tool across oncology, neurology, and cardiology; accurate coding of radiopharmaceutical supply affects clinical documentation, inventory tracking, and payment for imaging episodes.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for FDG PET dosing and typical sites of service, followed by benchmarks and payer coverage patterns where available. The publication outlines common billing considerations tied to radiopharmaceutical supply codes, potential policy updates affecting reimbursement and billing practices, and the implications for facility claims and service-line revenue.

The content is organized to help revenue cycle and compliance teams, imaging service managers, and policy analysts understand how HCPCS Level II code A9552 is used, which payers commonly process these charges, and what operational and policy factors influence billing and coverage for FDG PET radiopharmaceuticals. Data not available in the input is noted where applicable.